Updated weekly
Peptide News & Analysis
Regulatory decisions, trial readouts, and safety findings — each with the primary source and an explanation of why it matters. We cover what changed, not what a vendor wants to sell.
Regulatory · 2026-08-10What the FDA's 503A Category 2 List Actually Means for Peptide Access
The single most consequential regulatory action in the peptide space was not a ban — it was a bulk-substance classification that quietly removed BPC-157, CJC-1295, ipamorelin, and thymosin alpha-1 from lawful US compounding.
Retatrutide Phase III Data Sets a New Ceiling for Weight-Loss Pharmacology
The triple GIP/GLP-1/glucagon agonist has carried a ~24% Phase II weight-loss figure into Phase III, and the mechanistic addition of glucagon agonism is what makes the result interesting rather than merely larger.
Safety · 2026-07-15Independent Testing Keeps Finding the Same Problem in Grey-Market Peptide Vials
Mass-spectrometry analyses of consumer-purchased research peptides continue to report under-dosing, incorrect sequences, and endotoxin contamination in a meaningful fraction of samples.
Regulatory · 2026-06-30Australia Remains the Strictest Peptide Jurisdiction in the Developed World
Schedule 4 and Schedule 10 classifications, criminal importation penalties, and an active sports-integrity apparatus make Australian peptide enforcement categorically different from US or European practice.
Research · 2026-06-12The Lean-Mass Question Is Now the Most Important Open Problem in Incretin Therapy
Roughly a quarter to two-fifths of weight lost on semaglutide or tirzepatide is lean tissue absent resistance training and adequate protein — proportionally similar to caloric restriction, but occurring at far greater total magnitude.
Industry · 2026-05-20The End of the Shortage Loophole Reshaped the Compounded GLP-1 Market
Compounded semaglutide and tirzepatide were lawful only while the reference products sat on the FDA shortage list. Once resolved, that pathway closed, and enforcement shifted to telehealth marketers.
Regulatory · 2026-04-18How WADA's S0 and S2 Categories Capture Almost Every Popular Peptide
Tested athletes have effectively no compliant peptide options outside approved therapeutic use exemptions: S0 covers any non-approved substance, and S2 covers growth factors and secretagogues.
Research · 2026-03-25Oral Peptide Delivery Is Finally Producing Usable Bioavailability
Absorption enhancers such as SNAC, and newer small-molecule GLP-1 agonists, are eroding the injection requirement that has defined peptide therapeutics since insulin.
Every development, once a week
One email. Regulatory changes, new trial data, and safety findings.